140 filings
8-K
AKLI
Akili Inc
30 Apr 24
Akili Announces Amended Agreement with Shionogi, Shift in Corporate Strategy and Release Date for First Quarter 2024 Financial Results
8:14am
8-K
AKLI
Akili Inc
23 Apr 24
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:25pm
ARS
2023 FY
AKLI
Akili Inc
6 Mar 24
Annual report to shareholders
4:28pm
DEFA14A
AKLI
Akili Inc
6 Mar 24
Additional proxy soliciting materials
4:11pm
DEF 14A
AKLI
Akili Inc
Definitive proxy
6 Mar 24
4:07pm
S-8
883xv1uk
29 Feb 24
Registration of securities for employees
4:47pm
8-K
zbwg0vi 2rkd6lj
29 Feb 24
Akili Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
12:00am
8-K
4wwm1aadmcz uz
26 Feb 24
Japanese Product Now Under Review for Nationwide Marketing Approval
9:04am
PRE 14A
77750ddmjm g4uddmr3
23 Feb 24
Preliminary proxy
7:57am
8-K
zoxbczdasenr wqre
21 Feb 24
Akili Announces Release Date for Fourth Quarter and Full Year 2023
4:11pm
8-K
1wcqk lehd
5 Jan 24
Departure of Directors or Certain Officers
4:17pm
8-K
jm8835
20 Dec 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:58pm
8-K
1rwpsy8x 9c44qupsyf2
18 Dec 23
EndeavorRx®, World’s First and Only Prescription Video Game Treatment, Secures FDA Label Expansion for Pediatric ADHD Patients Aged 13-17
8:10am
8-K
vvrkcm
9 Nov 23
Akili Reports Third Quarter 2023 Financial Results and Provides Business Update
4:08pm
8-K
in3oa 6jg7h
27 Oct 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:20pm
8-K
19wpw3ibbww1j
6 Oct 23
Akili Announces Leadership Transition
7:07am
EFFECT
4zzwao7wnt
29 Sep 23
Notice of effectiveness
12:00am
POS AM
54zgni
27 Sep 23
Prospectus update (post-effective amendment)
7:45am